Clinical Trial Update: Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating optimization of enoxaparin dosing during PCI to improve anticoagulation management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention | Phase 4 | Status: COMPLETED